117 results on '"Skowasch, Dirk"'
Search Results
2. Assessing sleep-related breathing disorders among newly diagnosed rheumatoid and psoriatic arthritis patients: a cross-sectional study.
- Author
-
Petzinna, Simon M., Winter, Lone, Skowasch, Dirk, Pizarro, Carmen, Weber, Marcel, Kütting, Daniel, Behning, Charlotte, Bauer, Claus-Jürgen, and Schäfer, Valentin S.
- Subjects
PSORIATIC arthritis ,RHEUMATOID arthritis ,SLEEP apnea syndromes ,EPWORTH Sleepiness Scale ,CROSS-sectional method ,RESPIRATION ,MEDICAL screening - Abstract
Objectives: This cross-sectional study aimed to determine the prevalence and risk factors for sleep-related breathing disorders (SRBD) in newly diagnosed, untreated rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients, and to develop a screening algorithm for early detection. Methods: We evaluated newly diagnosed RA or PsA patients using the Epworth Sleepiness Scale (ESS) questionnaire, cardiorespiratory polygraphy (RPG), and clinical and laboratory assessments. Sleep apnea syndrome (SAS) was diagnosed based on pathological RPG findings excessive daytime sleepiness, defined as ESS score above 10. Results: The study included 39 patients (22 RA, 17 PsA) and 23 controls. In RPG, SRBD was identified in 38.5% of arthritis patients compared to 39.1% of controls (p = 1.00), with male gender (p =.004) and age (p <.001) identified as risk factors. Excessive daytime sleepiness was noted in 36.4% of RA patients, 17.6% of PsA patients, and 21.7% of controls. Of the 24 patients diagnosed with SRBD, 41.6% met the criteria for SAS. SAS prevalence was 31.8% among RA patients, 0% in PsA patients, and 13% in controls. A significant association was observed between excessive daytime sleepiness and SRBD (p =.036). Conclusion: Our findings reveal a high prevalence of SRBD in newly diagnosed, untreated RA and PsA patients in ESS and RPG, with excessive daytime sleepiness being a reliable predictor of SRBD. Patients with RA exhibited a higher predisposition to SAS. We therefore suggest incorporating ESS and RPG as screening tools in RA or PsA for early detection and management of SRBD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Discovering single cannabidiol or synergistic antitumor effects of cannabidiol and cytokine-induced killer cells on non-small cell lung cancer cells.
- Author
-
Yutao Li, Sharma, Amit, Hoffmann, Michèle J., Skowasch, Dirk, Essler, Markus, Weiher, Hans, and Schmidt-Wolf, Ingo G. H.
- Subjects
KILLER cells ,NON-small-cell lung carcinoma ,TRP channels ,TRPV cation channels ,CANNABIDIOL - Abstract
Introduction: A multitude of findings from cell cultures and animal studies are available to support the anti-cancer properties of cannabidiol (CBD). Since CBD acts on multiple molecular targets, its clinical adaptation, especially in combination with cancer immunotherapy regimen remains a serious concern. Methods: Considering this, we extensively studied the effect of CBD on the cytokine-induced killer (CIK) cell immunotherapy approach using multiple nonsmall cell lung cancer (NSCLC) cells harboring diverse genotypes. Results: Our analysis showed that, a) The Transient Receptor Potential Cation Channel Subfamily V Member 2 (TRPV2) channel was intracellularly expressed both in NSCLC cells and CIK cells. b) A synergistic effect of CIK combined with CBD, resulted in a significant increase in tumor lysis and Interferon gamma (IFNg) production. c) CBD had a preference to elevate the CD25+CD69+ population and the CD62L_CD45RA+terminal effector memory (EMRA) population in NKTCIK cells, suggesting early-stage activation and effector memory differentiation in CD3+CD56+ CIK cells. Of interest, we observed that CBD enhanced the calcium influx, which was mediated by the TRPV2 channel and elevated phosphor-Extracellular signal-Regulated Kinase (p-ERK) expression directly in CIK cells, whereas ERK selective inhibitor FR180204 inhibited the increasing cytotoxic CIK ability induced by CBD. Further examinations revealed that CBD induced DNA double-strand breaks via upregulation of histone H2AX phosphorylation in NSCLC cells and the migration and invasion ability of NSCLC cells suppressed by CBD were rescued using the TRPV2 antagonist (Tranilast) in the absence of CIK cells. We further investigated the epigenetic effects of this synergy and found that adding CBD to CIK cells decreased the Long Interspersed Nuclear Element-1 (LINE-1) mRNA expression and the global DNA methylation level in NSCLC cells carrying KRAS mutation. We further investigated the epigenetic effects of this synergy and found that adding CBD to CIK cells decreased the Long Interspersed Nuclear Element-1 (LINE-1) mRNA expression and the global DNA methylation level in NSCLC cells carrying KRAS mutation. Conclusions: Taken together, CBD holds a great potential for treating NSCLC with CIK cell immunotherapy. In addition, we utilized NSCLC with different driver mutations to investigate the efficacy of CBD. Our findings might provide evidence for CBD-personized treatment with NSCLC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Disease trajectories in interstitial lung diseases – data from the EXCITING-ILD registry.
- Author
-
Buschulte, Katharina, Kabitz, Hans-Joachim, Hagmeyer, Lars, Hammerl, Peter, Esselmann, Albert, Wiederhold, Conrad, Skowasch, Dirk, Stolpe, Christoph, Joest, Marcus, Veitshans, Stefan, Höffgen, Marc, Maqhuzu, Phillen, Schwarzkopf, Larissa, Hellmann, Andreas, Pfeifer, Michael, Behr, Jürgen, Karpavicius, Rainer, Günther, Andreas, Polke, Markus, and Höger, Philipp
- Subjects
INTERSTITIAL lung diseases ,LUNGS ,PROGRESSION-free survival ,IDIOPATHIC pulmonary fibrosis ,VITAL capacity (Respiration) ,SURVIVAL rate ,SURVIVAL analysis (Biometry) ,MULTIVARIATE analysis - Abstract
Background: Interstitial lung diseases (ILD) comprise a heterogeneous group of mainly chronic lung diseases with different disease trajectories. Progression (PF-ILD) occurs in up to 50% of patients and is associated with increased mortality. Methods: The EXCITING-ILD (Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases) registry was analysed for disease trajectories in different ILD. The course of disease was classified as significant (absolute forced vital capacity FVC decline > 10%) or moderate progression (FVC decline 5–10%), stable disease (FVC decline or increase < 5%) or improvement (FVC increase ≥ 5%) during time in registry. A second definition for PF-ILD included absolute decline in FVC % predicted ≥ 10% within 24 months or ≥ 1 respiratory-related hospitalisation. Risk factors for progression were determined by Cox proportional-hazard models and by logistic regression with forward selection. Kaplan-Meier curves were utilised to estimate survival time and time to progression. Results: Within the EXCITING-ILD registry 28.5% of the patients died (n = 171), mainly due to ILD (n = 71, 41.5%). Median survival time from date of diagnosis on was 15.5 years (range 0.1 to 34.4 years). From 601 included patients, progression was detected in 50.6% of the patients (n = 304) with shortest median time to progression in idiopathic NSIP (iNSIP; median 14.6 months) and idiopathic pulmonary fibrosis (IPF; median 18.9 months). Reasons for the determination as PF-ILD were mainly deterioration in lung function (PFT; 57.8%) and respiratory hospitalisations (40.6%). In multivariate analyses reduced baseline FVC together with age were significant predictors for progression (OR = 1.00, p < 0.001). Higher GAP indices were a significant risk factor for a shorter survival time (GAP stage III vs. I HR = 9.06, p < 0.001). A significant shorter survival time was found in IPF compared to sarcoidosis (HR = 0.04, p < 0.001), CTD-ILD (HR = 0.33, p < 0.001), and HP (HR = 0.30, p < 0.001). Patients with at least one reported ILD exacerbation as a reason for hospitalisation had a median survival time of 7.3 years (range 0.1 to 34.4 years) compared to 19.6 years (range 0.3 to 19.6 years) in patients without exacerbations (HR = 0.39, p < 0.001). Conclusion: Disease progression is common in all ILD and associated with increased mortality. Most important risk factors for progression are impaired baseline forced vital capacity and higher age, as well as acute exacerbations and respiratory hospitalisations for mortality. Early detection of progression remains challenging, further clinical criteria in addition to PFT might be helpful. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Therapie der Sarkoidose. Ein Positionspapier der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin (DGP).
- Author
-
Skowasch, Dirk, Bonella, Francesco, Buschulte, Katharina, Kneidinger, Nikolaus, Korsten, Peter, Kreuter, Michael, Müller-Quernheim, Joachim, Pfeifer, Michael, Prasse, Antje, Quadder, Bernd, Sander, Oliver, Schupp, Jonas C., Sitter, Helmut, Stachetzki, Bernd, and Grohé, Christian
- Published
- 2024
- Full Text
- View/download PDF
6. Allergische bronchopulmonale Aspergillose (ABPA) – ein Update.
- Author
-
Joest, Marcus, Klein, Johanna, Kütting, Daniel, and Skowasch, Dirk
- Published
- 2024
- Full Text
- View/download PDF
7. Sarkoidose – Mechanismen und Bildgebung.
- Author
-
Gaertner, Florian Christoph and Skowasch, Dirk
- Published
- 2024
- Full Text
- View/download PDF
8. Impact of interstitial lung disease on left ventricular myocardial function.
- Author
-
Stumpf, Max Jonathan, Wirtz, Marina Michaela Luise, Fleddermann, Max Fabian, Biener, Leonie, Weinhold, Leonie, Weber, Marcel, Schaefer, Christian Alexander, Nickenig, Georg, Skowasch, Dirk, and Pizarro, Carmen
- Subjects
INTERSTITIAL lung diseases ,SPECKLE tracking echocardiography ,GLOBAL longitudinal strain ,ECHOCARDIOGRAPHY ,LEFT heart ventricle ,VITAL capacity (Respiration) - Abstract
Background: Interstitial lung disease (ILD) comprises a wide variety of pulmonary parenchymal disorders within which progressive fibrosing ILD (PF-ILD) constitutes a phenotypic subset. By use of speckle tracking-based strain analysis we aimed to evaluate the degree of left ventricular (LV) dysfunction in progressive vs. non-progressive fibrosing ILD (non-PF-ILD). Methods: A total of 99 ILD patients (mean age 63.7 ± 13.5 years, 37.4% female), composed of 50 PF-ILD and 49 non-PF-ILD patients, and 33 controls were prospectively enrolled and underwent conventional and speckle tracking echocardiography. Additional laboratory and pulmonary function testing, as well as six-minute walk test were performed. Results: As compared to the non-PF-ILD cohort, PF-ILD patients exhibited a significantly impaired forced vital capacity (2.4 ± 1.0l vs. 3.1 ± 0.9l, p = 0.002), diffusion capacity for carbon monoxide (DL
CO , 25.6 ± 16.3% predicted vs. 43.6 ± 16.67% predicted, p <0.001) and exercise capacity response as measured by the six-minute walk test distance (268.1 ± 178.2m vs. 432.6 ± 94.2m, p <0.001). Contrary to conventional echocardiographic LV parameters, both regional and global longitudinal LV strain measurements were significantly altered in ILD patients as compared to controls. No differences in LV strain were found between both patient groups. Significant correlations were observed between global longitudinal strain, on the one hand, and systemic inflammation markers, total lung capacity (TLC) and DLCO , on the other hand (high-sensitivity C-reactive protein: Pearson´s r = -0.30, p< 0.001; interleukin-6: Pearson´s r = -0.26, p = 0.007; TLC % predicted: Pearson´s r = 0.22, p = 0.02; DLCO % predicted: Pearson´s r = 0.21, p = 0.02). Conclusions: ILD is accompanied by LV dysfunction. LV functionality inversely correlates with the severity of the restrictive ventilatory defect and inflammation marker levels. These observations support the assumption of persistent low-grade systemic inflammation that may link systemic cardiovascular function to ILD status. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
9. Hospitalisation patterns in interstitial lung diseases: data from the EXCITING-ILD registry.
- Author
-
Buschulte, Katharina, Kabitz, Hans-Joachim, Hagmeyer, Lars, Hammerl, Peter, Esselmann, Albert, Wiederhold, Conrad, Skowasch, Dirk, Stolpe, Christoph, Joest, Marcus, Veitshans, Stefan, Höffgen, Marc, Maqhuzu, Phillen, Schwarzkopf, Larissa, Hellmann, Andreas, Pfeifer, Michael, Behr, Jürgen, Karpavicius, Rainer, Günther, Andreas, Polke, Markus, and Höger, Philipp
- Subjects
INTERSTITIAL lung diseases ,HOSPITAL care ,CONNECTIVE tissue diseases ,PULMONARY hypertension ,PROGRESSION-free survival - Abstract
Background: Interstitial lung diseases (ILD) comprise a heterogeneous group of mainly chronic lung diseases with more than 200 entities and relevant differences in disease course and prognosis. Little data is available on hospitalisation patterns in ILD. Methods: The EXCITING-ILD (Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases) registry was analysed for hospitalisations. Reasons for hospitalisation were classified as all cause, ILD-related and respiratory hospitalisations, and patients were analysed for frequency of hospitalisations, time to first non-elective hospitalisation, mortality and progression-free survival. Additionally, the risk for hospitalisation according to GAP index and ILD subtype was calculated by Cox proportional-hazard models as well as influencing factors on prediction of hospitalisation by logistic regression with forward selection. Results: In total, 601 patients were included. 1210 hospitalisations were recorded during the 6 months prior to registry inclusion until the last study visit. 800 (66.1%) were ILD-related, 59.3% of admissions were registered in the first year after inclusion. Mortality was associated with all cause, ILD-related and respiratory-related hospitalisation. Risk factors for hospitalisation were advanced disease (GAP Index stages II and III) and CTD (connective tissue disease)-ILDs. All cause hospitalisations were associated with pulmonary hypertension (OR 2.53, p = 0.005). ILD-related hospitalisations were associated with unclassifiable ILD and concomitant emphysema (OR = 2.133, p = 0.001) as well as with other granulomatous ILDs and a positive smoking status (OR = 3.082, p = 0.005). Conclusion: Our results represent a crucial contribution in understanding predisposing factors for hospitalisation in ILD and its major impact on mortality. Further studies to characterize the most vulnerable patient group as well as approaches to prevent hospitalisations are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Phenotypes and treatment outcomes in idiopathic pulmonary arterial hypertension patients with comorbidities.
- Author
-
Skowasch, Dirk, Klose, Hans, Ewert, Ralf, Wilkens, Heinrike, Richter, Manuel, Rosenkranz, Stephan, Setzer, Gesine, Grünig, Ekkehard, and Halank, Michael
- Published
- 2024
- Full Text
- View/download PDF
11. Diagnostik und Therapie der pulmonalarteriellen Hypertonie.
- Author
-
Pizarro, Carmen, Nickenig, Georg, and Skowasch, Dirk
- Published
- 2023
- Full Text
- View/download PDF
12. Pulmonale Hypertonie assoziiert mit Lungenerkrankungen.
- Author
-
Halank, Michael, Zeder, Katarina E., Sommer, Natascha, Ulrich, Silvia, Held, Matthias, Köhler, Thomas, Foris, Vasile, Heberling, Melanie, Neurohr, Claus, Ronczka, Julia, Holt, Stephan, Skowasch, Dirk, Kneidinger, Nikolaus, and Behr, Jürgen
- Published
- 2023
- Full Text
- View/download PDF
13. Medikamentöse Therapie der pulmonalarteriellen Hypertonie mit Komorbiditäten – Welche Phänotypen gibt es, was gibt es zu beachten?
- Author
-
Grünig, Ekkehard, Halank, Michael, Neurohr, Claus, Behr, Jürgen, Milger-Kneidinger, Katrin, Ronczka, Julia, Lichtblau, Mona, Benjamin, Nicola, Lange, Tobias J., Ulrich, Silvia, Wilkens, Heinrike, Grohé, Christian, and Skowasch, Dirk
- Published
- 2023
- Full Text
- View/download PDF
14. Cardiac autonomic dysfunction in adult congenital heart disease.
- Author
-
Pizarro, Carmen, Bosse, Franziska Luise, Begrich, Charlotte, Reznakova, Barbora, Beiert, Thomas, Schrickel, Jan Wilko, Nickenig, Georg, Skowasch, Dirk, and Momcilovic, Diana
- Subjects
CONGENITAL heart disease ,ARRHYTHMIA ,HEART beat ,DYSAUTONOMIA ,PROGNOSIS - Abstract
Purpose: Due to recent advances in diagnosis and treatment, the number of adults with congenital heart disease (ACHD) has substantially increased. This achievement is mitigated by rhythm disorders. Here, we sought to determine alterations in heart rate variability (HRV) and their prognostic value in ACHD. Methods: Ninety seven ACHD patients (39.2 ± 14.1 years, 51.5% female) and 19 controls (39.7 ± 15.0 years, 47.4% female) underwent 24-h Holter monitoring. Results: As compared to controls, ACHD patients offered a significantly higher burden of premature ventricular contractions (p = 0.02) and decreased HRV indices (natural logarithmic transformation of very low frequency (lnVLF): 7.46 ± 0.76 ms
2 vs. 7.91 ± 0.92ms2 , p = 0.03; natural logarithmic transformation of low frequency (lnLF): 6.39 ± 0.95ms2 vs. 7.01 ± 1.07ms2 , p = 0.01; natural logarithmic transformation of the ratio of low to high frequency spectra (lnLF/HF): 0.81 ± 0.74 vs. 1.17 ± 0.51, p = 0.04). No differences in HRV measures were observed across ACHD lesion groups. NT-proBNP levels were significantly related to both time and frequency domain indices (natural logarithmic transformation of the standard deviation of NN intervals (lnSDNN): Spearman´s rho = -0.32, p = 0.001; natural logarithmic transformation of the standard deviation of the average NN intervals for each 5-min segment of a 24-h Holter monitoring (lnSDANN): Spearman´s rho: -0.33, p = 0.001; natural logarithmic transformation of the total power (lnTP): Spearman´s rho: -0.25, p = 0.01; lnVLF: Spearman´s rho: -0.33, p = 0.001; lnLF: Spearman´s rho: -0.35, p < 0.001; lnLF/HF: Spearman´s rho: -0.34, p = 0.001). After a mean follow-up of 3.9 ± 0.7 years, 8 patients died and 3 patients survived sudden cardiac death (SCD). Several HRV parameters were significantly higher in event-free ACHD patients than in those who died or survived SCD (natural logarithmic transformation of the average of the standard deviations of NN intervals for each 5-min segment of a 24-h Holter monitoring (lnASDNN): p = 0.04; lnPNN30: p = 0.04; lnVFL: p = 0.03; lnLF: p < 0.01). On univariate Cox regression analysis, the time domain indices lnSDNN, lnASDNN and lnPNN30, as well as the frequency domain parameters lnTP, lnVLF and lnLF were associated with death and survived cardiac arrest. Conclusion: ACHD is accompanied by HRV impairment that carries prognostic implications on ACHD mortality and survived SCD. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
15. Health Care Situation in the Treatment of Uncontrolled GINA Step 4/5 Patients in Germany.
- Author
-
Timmermann, Hartmut, Milger, Katrin, Virchow, Johann Christian, Schmidt, Olaf, Bergmann, Karl-Christian, Koschel, Dirk, Neurohr, Claus, Scholz, Florian, Heck, Sebastian, and Skowasch, Dirk
- Subjects
MEDICAL personnel ,ASTHMATICS ,PULMONOLOGISTS ,MEDICAL care ,MEDICAL record databases ,GENERAL practitioners - Abstract
Purpose: It has been estimated that, in 2019, 54,000 patients in Germany had uncontrolled GINA step 4/5 asthma. In the current study we analyzed which health care providers were involved in the management of these patients and their role in disease phenotyping.Patients and Methods: The year 2019 was retrospectively analyzed using the IQVIA
TM LRx, a longitudinal anonymized prescription database, and the electronic, anonymized medical records database, the IQVIA Disease Analyzer.Results: Of 54,000 uncontrolled GINA step 4/5 asthma patients in Germany, 52% had consulted both general practitioners (GPs) and pulmonologists, and 48% were seen exclusively by a GP. Of these 54,000 patients, 45% were being prescribed and were thus overusing short-acting β 2-agonists (SABAs) and oral corticosteroids (OCS) for ≥ 2 years, 26% for ≥ 3 years, and 16% for ≥ 4 years. In most regions, pulmonologists saw one of their uncontrolled GINA step 4/5 asthma patients per week. Laboratory tests from consultations with a GP were available for only 10% of patients referred to a pulmonologist. In 50% of uncontrolled asthma patients treated according to GINA step 4/5, these were initiated by the pulmonologist, and 34% received laboratory testing within the first year (in GINA step 4/5 asthma, the numbers are 20% and 18%, respectively).Conclusion: Fifty percent of uncontrolled asthma patients treated according to GINA step 4/5 were regularly seen by pulmonologists, who performed most of the phenotyping confirming their importance in the management of severe, uncontrolled asthma in Germany. To understand treatment pathways for these patients, further studies are needed. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
16. Preclinical atherosclerotic burden in carotid and lower extremity arteries in adults with congenital heart disease.
- Author
-
Momcilovic, Diana, Begrich, Charlotte, Stumpf, Max Jonathan, Bosse, Franziska, Reznakova, Barbora, Schaefer, Christian Alexander, Schahab, Nadjib, Nickenig, Georg, Skowasch, Dirk, and Pizarro, Carmen
- Published
- 2023
- Full Text
- View/download PDF
17. Kommentar zu „Benralizumab reduziert Kortikosteroid-Bedarf".
- Author
-
Skowasch, Dirk
- Published
- 2024
- Full Text
- View/download PDF
18. Kommentar zu „Benralizumab reduziert Kortikosteroid-Bedarf".
- Author
-
Skowasch, Dirk
- Published
- 2024
- Full Text
- View/download PDF
19. Impact of short-term pausing of oral corticosteroids on blood eosinophil count in patients with severe asthma.
- Author
-
Biener, Leonie, Milger, Katrin, Suhling, Hendrik, Korn, Stephanie, Pizarro, Carmen, and Skowasch, Dirk
- Published
- 2023
- Full Text
- View/download PDF
20. Prevalence of sleep-disordered breathing in patients with mitral regurgitation and the effect of mitral valve repair.
- Author
-
Biener, Leonie, Vogelhuber, Johanna, Alboany, Haron, Tiyerili, Vedat, Weber, Marcel, Linhart, Markus, Becher, Marc Ulrich, Schenk, Alina, Nickenig, Georg, Skowasch, Dirk, and Pizarro, Carmen
- Abstract
Purpose: The relationship between chronic heart failure and sleep-disordered breathing (SDB) has been frequently described. However, little is known about the association of mitral regurgitation (MR) and SDB or the impact of transcatheter mitral valve repair (TMVR) on SDB. Our aims were first to determine the prevalence of SDB in patients with MR, and second to determine the effect of TMVR on SDB. Methods: Patients with MR being evaluated for TMVR at the University Hospital Bonn underwent polygraphy (PG) to determine the prevalence of SDB. After TMVR, a subset of patients was followed up with transthoracic echocardiography (TTE) and PG to evaluate the effect of TMVR on SDB. Results: In 53 patients, mean age was 76.0 ± 8.5 years and 62% were male. Patients predominantly had more than moderate mitral regurgitation (94%). SDB was highly prevalent (68%) with predominantly central sleep apnoea (CSA, 67%). After TMVR in 15 patients, the apnoea/hypopnoea index (AHI) and central apnoea index (AI) were significantly reduced among patients with SDB (AHI − 8.0/h, p = 0.021; central AI − 6.9/h, p = 0.046). The left atrial volume index (LAVI) at baseline was significantly higher in patients with CSA than in patients with obstructive sleep apnoea (OSA) and was significantly reduced after TMVR (63.5 ml/m
2 ± 27.2 vs. 38.3 ml/m2 ± 13.0; − 18.4 ml/m2 , p = 0.027). Conclusion: SDB, especially CSA, is highly prevalent in patients with mitral regurgitation. In the follow-up cohort TMVR led to a significant reduction of the AHI, predominantly of central events. The findings of the study suggest that TMVR may be a suitable therapy not only for MR but also for the accompanying CSA. LAVI may be a useful indicator for CSA in patients with MR. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
21. Relevance of serum levels of the endoplasmic reticulum stress protein GRP78 (glucose-regulated protein 78 kDa) as biomarker in pulmonary diseases.
- Author
-
Al Zaidi, Muntadher, Marggraf, Vanessa, Repges, Elena, Nickenig, Georg, Skowasch, Dirk, Aksoy, Adem, and Pizarro, Carmen
- Abstract
Cellular stress and inflammation contribute to the initiation and progression of a variety of pulmonary diseases. Endoplasmic reticulum (ER) stress and its main regulator GRP78 (glucose-regulated protein 78 kDa) appear to be involved in the pathogenesis of pulmonary diseases, and GRP78 was found to be a biomarker in a wide range of inflammatory diseases. The aim of this study was to investigate the relevance of serum GRP78 in pulmonary disorders. In this prospective cohort study, 78 consecutive patients with chronic obstructive pulmonary disease (COPD, n = 28), asthma (n = 38) or interstitial lung disease (ILD, n = 12) underwent measurement of serum GRP78 levels by ELISA. The mean age of patients was 59.8 ± 12.4 years, 48.7% were female. Patients with elevated GRP78 levels (> median) offered a significantly better oxygenation status (capillary pO2: 75.3 ± 11.7 mmHg vs. 67.8 ± 15.9 mmHg, p = 0.02). Significant correlations were observed between GRP78, on the one hand, and haemoglobin, high-sensitivity C-reactive protein (hs-CRP) and eosinophil counts, on the other hand (haemoglobin: Pearson's r = −0.25, hs-CRP: r = 0.30, eosinophils: r = 0.63). Subsequently, we evaluated GRP78 measurements in function of severity stratifiers of the specific underlying pulmonary disease. ILD patients with a severe diffusion impairment (DL
CO < 40% of predicted), exhibited a significant decrease in GRP78 levels (p = 0.01). In COPD and asthma, both characterized by obstructive ventilatory defects, a forced expiratory volume in one second (FEV1 ) <30% of predicted was accompanied by significantly lower GRP78 (p = 0.0075). In both obstructive and restrictive pulmonary disorders, GRP78 protein concentrations were reduced with increasing disease severity. These data suggest a prevalent role of GRP78 in the presently studied pulmonary disorders. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
22. Real-World Experience on the Use of Mepolizumab from the Severe Asthma Registry of the German Asthma Net (MepoGAN-Study).
- Author
-
Korn, Stephanie, Milger, Katrin, Skowasch, Dirk, Schulz, Christian, Mohrlang, Cordula, Wernitz, Martin, Paulsson, Thomas, Hennig, Michael, and Buhl, Roland
- Subjects
ASTHMATICS ,ASTHMA ,SYMPTOMS ,MEDICAL registries ,MONOCLONAL antibodies ,WHEEZE - Abstract
Purpose: The German Asthma Net (GAN) operates a Severe Asthma Registry that provides an overview of the clinical presentation and management of patients with severe asthma. Based upon data from the GAN registry, the MepoGAN study aimed to describe clinical profiles and treatment outcomes of patients who were treated with the anti-IL-5 monoclonal antibody mepolizumab (Nucala
TM ) in routine practice in Germany. Patients and Methods: The MepoGAN study is a descriptive retrospective non-interventional cohort study. Mepolizumab patients enrolled in the GAN registry were evaluated with results being described in two different data sets: Cohort 1 (n=131) started on mepolizumab when the patients entered the registry. Results were reported after 4 months of therapy. Patients in Cohort 2 (n=220) were on treatment with mepolizumab at the time of enrollment and follow-up data were collected after a further year of treatment. Outcome measures included asthma control, lung function, disease symptoms, OCS use, and exacerbations. Results: Patients enrolled in the registry who started on mepolizumab in Cohort 1 had a mean age of 55 years, were former smokers in 51% of the cases, had a mean blood eosinophil count of 500 cells/μL, and frequently had maintenance OCS use (55%). In this real-world setting, mepolizumab therapy was associated with a clinically relevant reduction in blood eosinophils (− 445.7 cells/μL), OCS use (− 30%), and improvement in asthma control. Fifty-five percent (vs 10% at baseline) of the patients reported controlled or partially controlled asthma 4 months after starting therapy. In patients who were already treated with mepolizumab at registry enrollment (Cohort 2), asthma control and lung function remained stable after a further year of observation. Conclusion: The GAN registry data confirm the effectiveness of mepolizumab in a real-world setting. Treatment benefits are maintained over time. While the asthma of patients treated in routine practice was more severe, the results observed with mepolizumab are broadly consistent with RCTs. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
23. High prevalence of peripheral and carotid artery disease in patients with interstitial lung diseases.
- Author
-
Stumpf, Max Jonathan, Fleddermann, Max Fabian, Wirtz, Marina Michaela Luise, Biener, Leonie, Weinhold, Leonie, Schahab, Nadjib, Weber, Marcel, Nickenig, Georg, Skowasch, Dirk, Schaefer, Christian Alexander, and Pizarro, Carmen
- Published
- 2023
- Full Text
- View/download PDF
24. Kriterien zur Evaluation des Ansprechens auf Biologika bei schwerem Asthma – der Biologics Asthma Response Score (BARS).
- Author
-
Milger, Katrin, Korn, Stephanie, Feder, Claudia, Fuge, Jan, Mühle, Andreas, Schütte, Wolfgang, Skowasch, Dirk, Timmermann, Hartmut, and Suhling, Hendrik
- Published
- 2023
- Full Text
- View/download PDF
25. Pre-Analytical Evaluation of Streck Cell-Free DNA Blood Collection Tubes for Liquid Profiling in Oncology.
- Author
-
Diaz, Inga Medina, Nocon, Annette, Held, Stefanie A. E., Kobilay, Makbule, Skowasch, Dirk, Bronkhorst, Abel J., Ungerer, Vida, Fredebohm, Johannes, Diehl, Frank, Holdenrieder, Stefan, and Holtrup, Frank
- Subjects
CELL-free DNA ,CIRCULATING tumor DNA ,NON-small-cell lung carcinoma ,TUBES ,GENETIC load - Abstract
Excellent pre-analytical stability is an essential precondition for reliable molecular profiling of circulating tumor DNA (ctDNA) in oncological diagnostics. Therefore, in vitro degradation of ctDNA and the additional release of contaminating genomic DNA from lysed blood cells must be prevented. Streck Cell-Free DNA blood collection tubes (cfDNA BCTs) have proposed advantages over standard K
2 EDTA tubes, but mainly have been tested in healthy individuals. Blood was collected from cancer patients (n = 53) suffering from colorectal (n = 21), pancreatic (n = 11), and non-small-cell lung cancer (n = 21) using cfDNA BCT tubes and K2 EDTA tubes that were processed immediately or after 3 days (BCTs) or 6 hours (K2 EDTA) at room temperature. The cfDNA isolated from these samples was characterized in terms of yield using LINE-1 qPCR; the level of gDNA contamination; and the mutation status of KRAS, NRAS, and EGFR genes using BEAMing ddPCR. CfDNA yield and gDNA levels were comparable in both tube types and were not affected by prolonged storage of blood samples for at least 3 days in cfDNA BCTs or 6 hours in K2 EDTA tubes. In addition, biospecimens collected in K2 EDTA tubes and cfDNA BCTs stored for up to 3 days demonstrated highly comparable levels of mutational load across all respective cancer patient cohorts and a wide range of concentrations. Our data support the applicability of clinical oncology specimens collected and stored in cfDNA BCTs for up to 3 days for reliable cfDNA and mutation analyses. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
26. Hämoptysen.
- Author
-
Pizarro, Carmen, Meyer, Carsten, Schmidt, Joachim, and Skowasch, Dirk
- Published
- 2023
- Full Text
- View/download PDF
27. Testen Sie Ihr Fachwissen.
- Author
-
Pizarro, Carmen, Meyer, Carsten, Nickenig, Georg, and Skowasch, Dirk
- Published
- 2023
- Full Text
- View/download PDF
28. Kommentar zu „Benralizumab reduziert Kortikosteroid-Bedarf".
- Author
-
Skowasch, Dirk
- Published
- 2024
- Full Text
- View/download PDF
29. Crossover Patient Outcomes for Targeted Lung Denervation in Moderate to Severe Chronic Obstructive Pulmonary Disease: AIRFLOW-2.
- Author
-
Conway, Francesca, Tonkin, James, Valipour, Arschang, Pison, Christophe, Schumann, Christian, Bonta, Peter I., Kessler, Romain, Gesierich, Wolfgang, Darwiche, Kaid, Lamprecht, Bernd, Skowasch, Dirk, Johnson, Philip J., Slebos, Dirk-Jan, and Shah, Pallav L.
- Subjects
LUNG physiology ,INNERVATION of the lungs ,RESEARCH ,PATIENT aftercare ,DENERVATION ,TREATMENT effectiveness ,RANDOMIZED controlled trials ,OBSTRUCTIVE lung diseases ,BLIND experiment ,FORCED expiratory volume ,QUALITY of life ,CROSSOVER trials ,STATISTICAL sampling ,DISEASE exacerbation ,BRONCHOSCOPY - Abstract
Background: Targeted Lung Denervation (TLD) is a potential new therapy for COPD. Radiofrequency energy is bronchoscopically delivered to the airways to disrupt pulmonary parasympathetic nerves, to reduce bronchoconstriction, mucus hypersecretion, and bronchial hyperreactivity. Objectives: This work assesses the effect of TLD on COPD exacerbations (AECOPD) in crossover subjects in the AIRFLOW-2 trial. Method: The AIRFLOW-2 trial is a multicentre, randomized, double-blind, sham-controlled crossover trial of TLD in COPD. Patients with symptomatic COPD on optimal medical therapy with an FEV1 of 30–60% predicted received either TLD or sham bronchoscopy in a 1:1 randomization. Those in the sham arm had the opportunity to cross into the treatment arm after 12 months. The primary end point was rate of respiratory adverse events. Secondary end points included adverse events, changes in lung function and health-related quality of life and symptom scores. Results: Twenty patients were treated with TLD in the crossover phase and were subsequently followed up for 12 months (50% female, mean age 64.1 ± 6.9 years). After TLD, there was a trend towards a reduction in time to first AECOPD (hazard ratio 0.65, p = 0.28, not statistically significant) in comparison to sham follow-up period. There was also a reduction in time to first severe AECOPD in the crossover period (hazard ratio 0.38, p = 0.227, not statistically significant). Symptom scores and lung function showed stability. Conclusions: AIRFLOW-2 crossover data support that of the randomization phase, showing trends towards reduction in COPD exacerbations with TLD. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
30. Profiles and treatment patterns of patients with pulmonary arterial hypertension on monotherapy at experienced centres.
- Author
-
Wissmüller, Max, Xanthouli, Panagiota, Benjamin, Nicola, Grünig, Ekkehard, Richter, Manuel J., Gall, Henning, Ghofrani, Hossein Ardeschir, Herkenrath, Simon, Skowasch, Dirk, Pizarro, Carmen, Halank, Michael, Hohmann, Christopher, Hellmich, Martin, Gerhardt, Felix, and Rosenkranz, Stephan
- Subjects
PULMONARY arterial hypertension ,OLDER patients ,CONNECTIVE tissue diseases - Abstract
Aims: Guideline recommendations highlight the critical role of combination therapy for the treatment of pulmonary arterial hypertension (PAH). Conversely, registry data demonstrate that a considerable number of PAH patients remain on monotherapy. The reasons for this discrepancy remain elusive. The aim of this study was to assess the patient profiles, treatment patterns, and disease characteristics of patients diagnosed with PAH who were kept on monotherapy at experienced pulmonary hypertension (PH) centres and to capture potential reasons for monotherapy. Methods and results: We analysed the patient profiles of 182 patients on monotherapy with PAH‐targeted drugs, managed at experienced PH expert centres (Cologne, Giessen, Heidelberg, and Dresden). Patients were identified based on their latest follow‐up visit and analysed retrospectively from the time of PAH diagnosis to last follow‐up. Patients were dichotomized by age, and patient characteristics, treatment patterns, response to therapy, change in risk status, and drug tolerability were recorded during the course of their disease. Patients' mean age was 69.1 ± 13.1 years at the most recent follow‐up (Key Time Point 1) and 64.5 ± 14.9 years at the time of diagnosis (Key Time Point 2). The mean time on monotherapy was 60.7 ± 53.8 months; 35.7/64.3% of patients were male/female. The majority (66.5%) had idiopathic PAH, followed by PAH associated with connective tissue disease (17.0%) and portopulmonary PH (8.2%). Among patients on monotherapy, there were five main clusters: (i) patients with failed escalation attempts mostly because of intolerability (26.9%); (ii) low risk on monotherapy, favourable response, and no reason for escalation (24.2%); (iii) patients with mild PAH (36.3%); (iv) elderly patients with PAH and multiple co‐morbidities (38.5%); and (v) patients with associated forms of PAH where the level of evidence for combination therapies is considered low (16.5%). There were substantial differences between patients above or below the median age (68 years). The most frequently used monotherapy for PAH was phosphodiesterase type 5 inhibitors (75.3%). Conclusions: A considerable number of PAH patients are on monotherapy at large PH expert centres, characterized by specific reasons that justify this kind of treatment. Nevertheless, as comprehensive treatment strategies have shown improved long‐term outcomes even in mildly symptomatic patients, each case of monotherapy should be justified. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
31. ER-stress-induced secretion of circulating glucose-regulated protein 78kDa (GRP78) ameliorates pulmonary artery smooth muscle cell remodelling.
- Author
-
Al Zaidi, Muntadher, Pizarro, Carmen, Bley, Carolin, Repges, Elena, Sedaghat, Alexander, Zimmer, Sebastian, Jansen, Felix, Tiyerili, Vedat, Nickenig, Georg, Skowasch, Dirk, and Aksoy, Adem
- Abstract
Pulmonary arterial hypertension (PAH) is driven by vascular remodelling due to inflammation and cellular stress, including endoplasmic reticulum stress (ER stress). The main ER-stress chaperone, glucose-regulated protein 78 kDa (GRP78), is known to have protective effects in inflammatory diseases through extracellular signalling. The aim of this study is to investigate its significance in PAH. Human pulmonary arterial smooth muscle cells (PASMC) were stimulated with compounds that induce ER stress, after which the secretion of GRP78 into the cell medium was analysed by western blot. We found that when ER stress was induced in PASMC, there was also a time-dependent secretion of GRP78. Next, naïve PASMC were treated with conditioned medium (CM) from the ER-stressed donor PASMC. Incubation with CM from ER-stressed PASMC reduced the viability, oxidative stress, and expression of inflammatory and ER-stress markers in target cells. These effects were abrogated when the donor cells were co-treated with Brefeldin A to inhibit active secretion of GRP78. Direct treatment of PASMC with recombinant GRP78 modulated the expression of key inflammatory markers. Additionally, we measured GRP78 plasma levels in 19 PAH patients (Nice Group I) and correlated the levels to risk stratification according to ESC guidelines. Here, elevated plasma levels of GRP78 were associated with a favourable risk stratification. In conclusion, GRP78 is secreted by PASMC under ER stress and exhibits protective effects from the hallmarks of PAH in vitro. Circulating GRP78 may serve as biomarker for risk adjudication of patients with PAH. Proposed mechanism of ER-stress-induced GRP78 secretion by PASMC. Extracellular GRP78 can be measured as a circulating biomarker and is correlated with favourable clinical characteristics. Conditioned medium from ER-stressed PASMC reduces extensive viability, ROS formation, inflammation, and ER stress in target cells. These effects can be abolished by blocking protein secretion in donor cells by using Brefeldin A. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
32. Prevalence of Patients with Uncontrolled Asthma Despite NVL/GINA Step 4/5 Treatment in Germany.
- Author
-
Bergmann, Karl-Christian, Skowasch, Dirk, Timmermann, Hartmut, Lindner, Robert, Virchow, Johann Christian, Schmidt, Olaf, Koschel, Dirk, Neurohr, Claus, Heck, Sebastian, and Milger, Katrin
- Subjects
ASTHMATICS ,ELECTRONIC health records ,PANEL analysis - Abstract
Purpose: Asthma is one of the most prevalent chronic diseases in Germany affecting 4– 5% of all adults and 10% of children. Despite the availability of biologicals in recent years, studies show patients with inadequately controlled severe asthma in real life. The aim of the current study was to characterize and estimate the number of patients with NVL/GINA level 4 or 5 asthma and signs of poor control in Germany. Patients and Methods: In 2021, we retrospectively analyzed data collected during 2019 using the IQVIA™ LRx and IQVIA™ Disease Analyzer databases which contain anonymized longitudinal data covering approximately 80% of statutory health insurance (GKV) prescriptions in Germany with most relevant information about prescriptions, basic patient demographics or location of the prescriber; the IQVIA™ Disease Analyzer anonymized electronic medical records from a representative sample of office-based GPs and specialists. An expert committee of pulmonologists from different hospitals and expert practices supported the study. Asthma patients treated according to NVL/GINA 4/5 who used SABAs frequently (≥ 3 on days with no ICS-containing prescriptions/year) and/or received prescriptions for oral corticosteroids (OCS) (score of ≥ 2/year, a pulmonologist prescription scored 1.0, GP 0.75) were classified as severe, uncontrolled asthma. Results: In 2019, 3.4 million patients received at least two prescriptions of respiratory medications and 2.4 million patients on maintenance respiratory treatment have asthma. A total of 625,000 asthma patients were treated according to NVL/GINA step 4 or 5. Among these, 54,000 were uncontrolled according to the pre-defined OCS and/or SABA use, which corresponds to approximately 15% of patients in certain regions. Conclusion: In 2019, approximately 54,000 patients in Germany treated according to NVL/GINA step 4/5 had evidence suggestive for poor asthma control, up to 15% of patients in certain regions. Yet, only 12,000 patients overall were being treated with biologicals suggesting a possible treatment gap that requires further investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
33. Dupilumab bei chronisch-obstruktiver Lungenerkrankung.
- Author
-
Skowasch, Dirk and Nitschmann, Sirka
- Published
- 2024
- Full Text
- View/download PDF
34. A Combination of Cytokine-Induced Killer Cells With PD-1 Blockade and ALK Inhibitor Showed Substantial Intrinsic Variability Across Non-Small Cell Lung Cancer Cell Lines.
- Author
-
Li, Yutao, Sharma, Amit, Wu, Xiaolong, Weiher, Hans, Skowasch, Dirk, Essler, Markus, and Schmidt-Wolf, Ingo G. H.
- Subjects
KILLER cells ,NON-small-cell lung carcinoma ,PROGRAMMED cell death 1 receptors ,IMMUNE checkpoint proteins ,CANCER cells ,CRIZOTINIB ,ANAPLASTIC lymphoma kinase - Abstract
Background: Cancer heterogeneity poses a serious challenge concerning the toxicity and adverse effects of therapeutic inhibitors, especially when it comes to combinatorial therapies that involve multiple targeted inhibitors. In particular, in non-small cell lung cancer (NSCLC), a number of studies have reported synergistic effects of drug combinations in the preclinical models, while they were only partially successful in the clinical setup, suggesting those alternative clinical strategies (with genetic background and immune response) should be considered. Herein, we investigated the antitumor effect of cytokine-induced killer (CIK) cells in combination with ALK and PD-1 inhibitors in vitro on genetically variable NSCLC cell lines. Methods: We co-cultured the three genetically different NSCLC cell lines NCI-H2228 (EML4-ALK), A549 (KRAS mutation), and HCC-78 (ROS1 rearrangement) with and without nivolumab (PD-1 inhibitor) and crizotinib (ALK inhibitor). Additionally, we profiled the variability of surface expression multiple immune checkpoints, the concentration of absolute dead cells, intracellular granzyme B on CIK cells using flow cytometry as well as RT-qPCR. ELISA and Western blot were performed to verify the activation of CIK cells. Results: Our analysis showed that (a) nivolumab significantly weakened PD-1 surface expression on CIK cells without impacting other immune checkpoints or PD-1 mRNA expression, (b) this combination strategy showed an effective response on cell viability, IFN-γ production, and intracellular release of granzyme B in CD3
+ CD56+ CIK cells, but solely in NCI-H2228, (c) the intrinsic expression of Fas ligand (FasL) as a T-cell activation marker in CIK cells was upregulated by this additive effect, and (d) nivolumab induced Foxp3 expression in CD4+ CD25+ subpopulation of CIK cells significantly increased. Taken together, we could show that CIK cells in combination with crizotinib and nivolumab can enhance the anti-tumor immune response through FasL activation, leading to increased IFN-γ and granzyme B, but only in NCI-H2228 cells with EML4-ALK rearrangement. Therefore, we hypothesize that CIK therapy may be a potential alternative in NSCLC patients harboring EML4-ALK rearrangement, in addition, we support the idea that combination therapies offer significant potential when they are optimized on a patient-by-patient basis. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
35. Asthma-COPD-Overlap – diagnostisches und therapeutisches Management.
- Author
-
Skowasch, Dirk and Pizarro, Carmen
- Published
- 2021
- Full Text
- View/download PDF
36. NKG2D Engagement Alone Is Sufficient to Activate Cytokine-Induced Killer Cells While 2B4 Only Provides Limited Coactivation.
- Author
-
Wu, Xiaolong, Sharma, Amit, Oldenburg, Johannes, Weiher, Hans, Essler, Markus, Skowasch, Dirk, and Schmidt-Wolf, Ingo G. H.
- Subjects
KILLER cells ,GRAFT versus host disease ,CHIMERIC antigen receptors ,CELL populations - Abstract
Cytokine-induced killer (CIK) cells are an ex vivo expanded heterogeneous cell population with an enriched NK-T phenotype (CD3+CD56+). Due to the convenient and relatively inexpensive expansion capability, together with low incidence of graft versus host disease (GVHD) in allogeneic cancer patients, CIK cells are a promising candidate for immunotherapy. It is well known that natural killer group 2D (NKG2D) plays an important role in CIK cell-mediated antitumor activity; however, it remains unclear whether its engagement alone is sufficient or if it requires additional co-stimulatory signals to activate the CIK cells. Likewise, the role of 2B4 has not yet been identified in CIK cells. Herein, we investigated the individual and cumulative contribution of NKG2D and 2B4 in the activation of CIK cells. Our analysis suggests that (a) NKG2D (not 2B4) is implicated in CIK cell (especially CD3+CD56+ subset)-mediated cytotoxicity, IFN-γ secretion, E/T conjugate formation, and degranulation; (b) NKG2D alone is adequate enough to induce degranulation, IFN-γ secretion, and LFA-1 activation in CIK cells, while 2B4 only provides limited synergy with NKG2D (e.g., in LFA-1 activation); and (c) NKG2D was unable to costimulate CD3. Collectively, we conclude that NKG2D engagement alone suffices to activate CIK cells, thereby strengthening the idea that targeting the NKG2D axis is a promising approach to improve CIK cell therapy for cancer patients. Furthermore, CIK cells exhibit similarities to classical invariant natural killer (iNKT) cells with deficiencies in 2B4 stimulation and in the costimulation of CD3 with NKG2D. In addition, based on the current data, the divergence in receptor function between CIK cells and NK (or T) cells can be assumed, pointing to the possibility that molecular modifications (e.g., using chimeric antigen receptor technology) on CIK cells may need to be customized and optimized to maximize their functional potential. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
37. Zusammenfassung und Kommentierung der neuen europäischen Leitlinie zum Lungenhochdruck.
- Author
-
Grünig, Ekkehard, Benjamin, Nicola, Behr, Jürgen, Skowasch, Dirk, Milger-Kneidinger, Katrin, Halank, Michael, Kuebler, Wolfgang M., Kovacs, Gabor, Lichtblau, Mona, Guth, Stefan, Apitz, Christian, Kaemmerer, Harald, Tello, Khodr, and Ulrich, Silvia
- Published
- 2023
- Full Text
- View/download PDF
38. Aktuelle Entwicklungen in der Schlafforschung und Schlafmedizin – eine Einschätzung der AG „Herz- und Kreislauferkrankungen".
- Author
-
Stieglitz, Sven, Skowasch, Dirk, and Herberger, Sebastian
- Published
- 2022
- Full Text
- View/download PDF
39. Pulmonary Hypertension in Patients With COPD: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).
- Author
-
Vizza, Carmine Dario, Hoeper, Marius M., Huscher, Doerte, Pittrow, David, Benjamin, Nicola, Olsson, Karen M., Ghofrani, H. Ardeschir, Held, Matthias, Klose, Hans, Lange, Tobias, Rosenkranz, Stephan, Dumitrescu, Daniel, Badagliacca, Roberto, Claussen, Martin, Halank, Michael, Vonk-Noordegraaf, Anton, Skowasch, Dirk, Ewert, Ralf, Gibbs, J. Simon R., and Delcroix, Marion
- Subjects
PULMONARY hypertension ,OBSTRUCTIVE lung diseases ,SURVIVAL rate ,PHOSPHODIESTERASE-5 inhibitors ,VASCULAR resistance ,ANTIHYPERTENSIVE agents ,RESEARCH ,RESEARCH methodology ,ACQUISITION of data ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,PHOSPHODIESTERASE inhibitors ,LONGITUDINAL method ,DISEASE complications - Abstract
Background: Pulmonary hypertension (PH) in COPD is a poorly investigated clinical condition.Research Question: Which factors determine the outcome of PH in COPD?Study Design and Methods: We analyzed the characteristics and outcome of patients enrolled in the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) with moderate or severe PH in COPD as defined during the 6th PH World Symposium who received medical therapy for PH and compared them with patients with idiopathic pulmonary arterial hypertension (IPAH).Results: The population included incident patients with moderate PH in COPD (n = 68), with severe PH in COPD (n = 307), and with IPAH (n = 489). Patients with PH in COPD were older, predominantly male, and treated mainly with phosphodiesterase-5 inhibitors. Despite similar hemodynamic impairment, patients with PH in COPD achieved a worse 6-min walking distance (6MWD) and showed a more advanced World Health Organization functional class (WHO FC). Transplant-free survival rates at 1, 3, and 5 years were higher in the IPAH group than in the PH in COPD group (IPAH: 94%, 75%, and 55% vs PH in COPD: 86%, 55%, and 38%; P = .004). Risk factors for poor outcomes in PH in COPD were male sex, low 6MWD, and high pulmonary vascular resistance (PVR). In patients with severe PH in COPD, improvements in 6MWD by ≥ 30 m or improvements in WHO FC after initiation of medical therapy were associated with better outcomes.Interpretation: Patients with PH in COPD were functionally more impaired and had a poorer outcome than patients with IPAH. Predictors of death in the PH in COPD group were sex, 6MWD, and PVR. Our data raise the hypothesis that some patients with severe PH in COPD may benefit from PH treatment. Randomized controlled studies are necessary to explore this hypothesis further.Trial Registry: ClinicalTrials.gov; No.: NCT01347216; URL: www.clinicaltrials.gov. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
40. Endobronchial Coil System versus Standard-of-Care Medical Management in the Treatment of Subjects with Severe Emphysema.
- Author
-
Klooster, Karin, Valipour, Arschang, Marquette, Charles-Hugo, Boutros, Jacques, Mal, Hervé, Marceau, Armelle, Shah, Pallav L., Conway, Francesca, Deslée, Gaëtan, Bourdin, Arnaud, Pison, Christophe, Grah, Christian, Hetzel, Martin, Schumann, Christian, Kessler, Romain, Huebner, Ralf-Harto, Skowasch, Dirk, Darwiche, Kaid, Hammerl, Peter, and Stanzel, Franz
- Subjects
RESEARCH ,MEDICAL cooperation ,SEVERITY of illness index ,RANDOMIZED controlled trials ,DESCRIPTIVE statistics ,QUESTIONNAIRES ,LUNG surgery ,STATISTICAL sampling ,PULMONARY emphysema ,BRONCHOSCOPY - Abstract
Background: Bronchoscopic lung volume reduction using endobronchial coils is a new treatment for patients with severe emphysema. To date, the benefits have been modest and have been suggested to be much larger in patients with severe hyperinflation and nonmulti-comorbidity. Objective: We aimed to evaluate the efficacy and safety of endobronchial coil treatment in a randomized multicenter clinical trial using optimized patient selection. Method: Patients with severe emphysema on HRCT scan with severe hyperinflation (residual volume [RV] ≥200% predicted and RV/total lung capacity [TLC] >55%) were randomized to coil treatment or control. Primary outcome measures were differences in the forced expiratory volume in 1 s (FEV
1 ) and St George's Respiratory Questionnaire (SGRQ) total score at 6 months. Results: Due to premature study termination, a total of 120 patients (age 63 ± 7 years, FEV1 29 ± 7% predicted, RV 251 ± 41% predicted, RV/TLC 67 ± 6%, and SGRQ 58 ± 13 points), instead of 210 patients, were randomized. At study termination, 91 patients (57 coil and 34 control) had 6-month results available. Analyses showed significantly greater improvements in favor of the coil group. The increase in FEV1 was greater in the coil group than that in the control group by + 10.3 [+4.7 to +16.0] % and in SGRQ by −10.6 [−15.9 to −5.4] points. At study termination, there were 5 (6.8%) deaths in the coil cohort reported. Conclusion: Despite early study termination, coil treatment compared to control results in a significant improvement in the lung function and quality of life benefits for up to 6 months in patients with emphysema and severe hyperinflation. These improvements were of clinical importance but were associated with a higher likelihood of serious adverse events. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
41. No evidence to support the impact of migration background on treatment response rates and cancer survival: a retrospective matched-pair analysis in Germany.
- Author
-
Rüdiger, Roman, Geiser, Franziska, Ritter, Manuel, Brossart, Peter, Keyver-Paik, Mignon-Denise, Faridi, Andree, Vatter, Hartmut, Bootz, Friedrich, Landsberg, Jennifer, Kalff, Jörg C., Herrlinger, Ulrich, Kristiansen, Glen, Pietsch, Torsten, Aretz, Stefan, Thomas, Daniel, Radbruch, Lukas, Kramer, Franz-Josef, Strassburg, Christian P., Gonzalez-Carmona, Maria, and Skowasch, Dirk
- Abstract
Background: Immigration has taken the central stage in world politics, especially in the developed countries like Germany, where the continuous flow of immigrants has been well documented since 1960s. Strikingly, emerging data suggest that migrant patients have a poorer response to the treatment and lower survival rates in their new host country, raising concerns about health disparities. Herein, we present our investigation on the treatment response rate and cancer survival in German patients with and without an immigrant background that were treated at our comprehensive cancer center in Germany.Methods: Initially, we considered 8162 cancer patients treated at the Center for Integrated Oncology (CIO), University Hospital Bonn, Germany (April 2002-December 2015) for matched-pair analysis. Subsequently, the German patients with a migration background and those from the native German population were manually identified and catalogued using a highly specific name-based algorithm. The clinical parameters such as demographic characteristics, tumor characteristics, defined staging criteria, and primary therapy were further adjusted. Using these stringent criteria, a total of 422 patients (n = 211, Germans with migration background; n = 211, native German population) were screened to compare for the treatment response and survival rates (i.e., 5-year overall survival, progression-free survival, and time to progression).Results: Compared to the cohort with migration background, the cohort without migration background was slightly older (54.9 vs. 57.9 years) while having the same sex distribution (54.5% vs. 55.0% female) and longer follow-up time (36.9 vs. 42.6 months). We did not find significant differences in cancer survival (5-year overall survival, P = 0.771) and the response rates (Overall Remission Rate; McNemar's test, P = 0.346) between both collectives.Conclusion: Contrary to prior reports, we found no significant differences in cancer survival between German patients with immigrant background and native German patients. Nevertheless, the advanced treatment protocols implemented at our comprehensive cancer center may possibly account for the low variance in outcome. To conduct similar studies with a broader perspective, we propose that certain risk factors (country-of-origin-specific infections, dietary habits, epigenetics for chronic diseases etc.) should be considered, specially in the future studies that will recruit new arrivals from the 2015 German refugee crisis. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
42. Testen Sie Ihr Fachwissen.
- Author
-
Pizarro, Carmen, Meyer, Carsten, Nickenig, Georg, and Skowasch, Dirk
- Published
- 2023
- Full Text
- View/download PDF
43. Two-Year Outcomes for the Double-Blind, Randomized, Sham-Controlled Study of Targeted Lung Denervation in Patients with Moderate to Severe COPD: AIRFLOW-2.
- Author
-
Valipour, Arschang, Shah, Pallav L, Herth, Felix J, Pison, Christophe, Schumann, Christian, Hübner, Ralf-Harto, Bonta, Peter I, Kessler, Romain, Gesierich, Wolfgang, Darwiche, Kaid, Lamprecht, Bernd, Perez, Thierry, Skowasch, Dirk, Deslee, Gaetan, Marceau, Armelle, Sciurba, Frank C, Gosens, Reinoud, Hartman, Jorine E, Conway, Francesca, and Duller, Marina
- Published
- 2020
- Full Text
- View/download PDF
44. Higher number of multidisciplinary tumor board meetings per case leads to improved clinical outcome.
- Author
-
Freytag, Marius, Herrlinger, Ulrich, Hauser, Stefan, Bauernfeind, Franz G., Gonzalez-Carmona, Maria A., Landsberg, Jennifer, Buermann, Jens, Vatter, Hartmut, Holderried, Tobias, Send, Thorsten, Schumacher, Martin, Koscielny, Arne, Feldmann, Georg, Heine, Mario, Skowasch, Dirk, Schäfer, Niklas, Funke, Benjamin, Neumann, Michael, and Schmidt-Wolf, Ingo G. H.
- Subjects
PROGRESSION-free survival ,TUMORS ,DISEASE relapse - Abstract
Background: This analysis aims at evaluating the impact of multidisciplinary tumor boards on clinical outcome of multiple tumor entities, the effect of the specific number of multidisciplinary tumor boards and potential differences between the tumor entities.Methods: By a matched-pair analysis we compared the response to treatment, overall survival, relapse or disease free survival and progression free survival of patients whose cases were discussed in a tumor board meeting with patients whose cases were not. It was performed with patients registered in the cancer registry of the University of Bonn and diagnosed between 2010 and 2016. After the matching process with a pool of 7262 patients a total of 454 patients with 66 different tumor types were included in this study.Results: First, patients with three or more multidisciplinary tumor board meetings in their history show a significantly better overall survival than patients with no tumor board meeting. Second, response to treatment, relapse free survival and time to progression were not found to be significantly different. Third, there was no significant difference for a specific tumor entity.Conclusion: This study revealed a positive impact of a higher number of multidisciplinary tumor boards on the clinical outcome. Also, our analysis hints towards a positive effect of multidisciplinary tumor boards on overall survival. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
45. Clinical features of sarcoidosis patients presenting with head and neck manifestations – a two-center retrospective study and proposal of a diagnostic algorithm for the otorhinolaryngologist.
- Author
-
Send, Thorsten, Korsten, Peter, Bertlich3., Mattis, Braunwarth, Christoph, Bootz, Friedrich, Skowasch, Dirk, and Jakob, Mark
- Subjects
SARCOIDOSIS diagnosis ,THERAPEUTIC use of glucocorticoids ,OTOLARYNGOLOGISTS ,SARCOIDOSIS ,ACADEMIC medical centers ,AZATHIOPRINE ,COMBINATION drug therapy ,LUNGS ,RETROSPECTIVE studies ,LYMPH nodes ,DIFFERENTIAL diagnosis ,HEAD ,METHOTREXATE ,SYMPTOMS ,DESCRIPTIVE statistics ,NECK ,LONGITUDINAL method - Abstract
Background and Aims: We aimed to investigate the clinical characteristics of patients presenting with sarcoidosis of the head and neck as the initial manifestation and to provide recommendations for the diagnostic work-up for the practicing otorhinolaryngologist. Material and Methods: We performed a retrospective cohort study at two university medical centers in Germany. Patients with a histopathologically confirmed diagnosis of sarcoidosis treated in the otorhinolaryngology departments were analyzed. Results: We identified 62 patients (2003–2016). In total, 85.4% (n = 53) of patients received the initial diagnosis of sarcoidosis during their ENT treatment. Sarcoidosis was detected in the lymph nodes in 42.3% (n = 30) of the patients; 57.7% had extra-lymphatic manifestations. Fifteen patients (24.2%) showed pulmonary involvement. 30.6% (n = 19) were treated with oral glucocorticoids (GC) alone, three patients with GC and methotrexate, one patient initially received a combination of GC and azathioprine, one patient rejected the recommended treatment. Conclusions: Sarcoidosis should be considered as a differential diagnosis in patients presenting with head and neck symptoms. The most frequent presenting symptoms were cervical lymphadenopathy and affection of the paranasal sinuses. Therefore, otorhinolaryngologists should be aware of sarcoidosis and help guide referral strategies as they may be the first physicians treating these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
46. Endoscopic Lung Volume Reduction in COPD: The Impact of Coil Implantation on Patients' Physical Activity.
- Author
-
Biener, Leonie, Skowasch, Dirk, Hollmann, Sophia, Schreiber, Tina, Nickenig, Georg, Fimmers, Rolf, and Pizarro, Carmen
- Subjects
PULMONARY emphysema treatment ,ACADEMIC medical centers ,ACCELEROMETERS ,ENDOSCOPY ,ENERGY metabolism ,LONGITUDINAL method ,OBSTRUCTIVE lung diseases ,PNEUMONECTOMY ,QUALITY of life ,PHYSICAL activity - Abstract
Endoscopic lung volume reduction (ELVR) is an emerging therapy option for the treatment of severe emphysema in COPD. To which extent patients profit from lung volume reduction via coils (LVRC) regarding morbidity, mortality, and quality of life is not clear yet. In this monocentric prospective cohort study, 13 COPD patients with severe emphysema (residual volume [RV] >225%) were enrolled at the University Hospital of Bonn. Activity measurements were assessed by a validated accelerometer wristband. By LVRC, RV could be reduced by 0.13 L to 5.54 ± 1.29 L. We could show a clinically relevant improvement in patients' physical activity after LVRC, measured as daily step count (497.7 ± 72.6 vs. 1,913.7 ± 182.7 steps/day, p = 0.03) and mean daily active energy expenditure (714.4 ± 73.6 vs. 2,321.3 ± 163.9 joules, p = 0.03). This improvement in physical activity is possibly associated with a positive effect on patients' morbidity and mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
47. Clinical features of sarcoidosis patients presenting with head and neck manifestations – a two-center retrospective study and proposal of a diagnostic algorithm for the otorhinolaryngologist.
- Author
-
Send, Thorsten, Korsten, Peter, Bertlich, Mattis, Braunwarth, Christoph, Bootz, Friedrich, Skowasch, Dirk, and Jakob, Mark
- Subjects
THERAPEUTIC use of glucocorticoids ,SARCOIDOSIS diagnosis ,ACADEMIC medical centers ,COMBINATION drug therapy ,DIFFERENTIAL diagnosis ,GLUCOCORTICOIDS ,HEAD ,LUNGS ,LYMPH nodes ,MEDICAL records ,METHOTREXATE ,NECK ,SARCOIDOSIS ,SYMPTOMS ,RETROSPECTIVE studies ,AZATHIOPRINE ,DESCRIPTIVE statistics ,ACQUISITION of data methodology - Abstract
Copyright of Acta Oto-Laryngologica is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2020
- Full Text
- View/download PDF
48. Pseudoxanthoma elasticum – also a microvascular disease.
- Author
-
Stumpf, Max Jonathan, Mahn, Thorsten, Steinmetz, Martin, Fimmers, Rolf, Pizarro, Carmen, Nickenig, Georg, Skowasch, Dirk, Schahab, Nadjib, and Schaefer, Christian Alexander
- Published
- 2020
- Full Text
- View/download PDF
49. Safety and Adverse Events after Targeted Lung Denervation for Symptomatic Moderate to Severe Chronic Obstructive Pulmonary Disease (AIRFLOW). A Multicenter Randomized Controlled Clinical Trial.
- Author
-
Slebos, Dirk-Jan, Shah, Pallav L., Herth, Felix J. F., Pison, Christophe, Schumann, Christian, Hübner, Ralf-Harto, Bonta, Peter I., Kessler, Romain, Gesierich, Wolfgang, Darwiche, Kaid, Lamprecht, Bernd, Perez, Thierry, Skowasch, Dirk, Deslee, Gaetan, Marceau, Armelle, Sciurba, Frank C., Gosens, Reinoud, Hartman, Jorine E., Srikanthan, Karthi, and Duller, Marina
- Subjects
DENERVATION ,OBSTRUCTIVE lung diseases ,RANDOMIZED controlled trials ,BRONCHOSCOPY ,RESPIRATORY infections ,RESEARCH ,RESEARCH methodology ,EVALUATION research ,MEDICAL cooperation ,BRONCHODILATOR agents ,TREATMENT effectiveness ,COMPARATIVE studies ,FORCED expiratory volume ,BLIND experiment ,DISEASE complications - Abstract
Rationale: Targeted lung denervation (TLD) is a bronchoscopic radiofrequency ablation therapy for chronic obstructive pulmonary disease (COPD), which durably disrupts parasympathetic pulmonary nerves to decrease airway resistance and mucus hypersecretion.Objectives: To determine the safety and impact of TLD on respiratory adverse events.Methods: We conducted a multicenter, randomized, sham bronchoscopy-controlled, double-blind trial in patients with symptomatic (modified Medical Research Council dyspnea scale score, ≥2; or COPD Assessment Test score, ≥10) COPD (FEV1, 30-60% predicted). The primary endpoint was the rate of respiratory adverse events between 3 and 6.5 months after randomization (defined as COPD exacerbation, tachypnea, wheezing, worsening bronchitis, worsening dyspnea, influenza, pneumonia, other respiratory infections, respiratory failure, or airway effects requiring therapeutic intervention). Blinding was maintained through 12.5 months.Measurements and Main Results: Eighty-two patients (50% female; mean ± SD: age, 63.7 ± 6.8 yr; FEV1, 41.6 ± 7.3% predicted; modified Medical Research Council dyspnea scale score, 2.2 ± 0.7; COPD Assessment Test score, 18.4 ± 6.1) were randomized 1:1. During the predefined 3- to 6.5-month window, patients in the TLD group experienced significantly fewer respiratory adverse events than those in the sham group (32% vs. 71%, P = 0.008; odds ratio, 0.19; 95% confidence interval, 0.0750-0.4923, P = 0.0006). Between 0 and 12.5 months, these findings were not different (83% vs. 90%; P = 0.52). The risk of COPD exacerbation requiring hospitalization in the 0- to 12.5-month window was significantly lower in the TLD group than in the sham group (hazard ratio, 0.35; 95% confidence interval, 0.13-0.99; P = 0.039). There was no statistical difference in the time to first moderate or severe COPD exacerbation, patient-reported symptoms, or other physiologic measures over the 12.5 months of follow-up.Conclusions: Patients with symptomatic COPD treated with TLD combined with optimal pharmacotherapy had fewer study-defined respiratory adverse events, including hospitalizations for COPD exacerbation.Clinical trial registered with www.clinicaltrials.gov (NCT02058459). [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
50. Obstructive sleep apnea and atherosclerosis—update 2019.
- Author
-
Biener, Leonie, Pizarro, Carmen, Nickenig, Georg, and Skowasch, Dirk
- Subjects
SLEEP apnea syndromes ,CARDIOVASCULAR diseases ,CONTINUOUS positive airway pressure ,HYPERTENSION ,DISEASE risk factors - Abstract
Obstructive sleep apnea (OSA) is a common disorder that has been associated with an increased risk of atherosclerosis and its clinical manifestations. While treatment with continuous positive airway pressure (CPAP) has been shown to exert several beneficial effects on cardiovascular disease and prognosis in observational studies, CPAP was not effective in three recent randomized controlled trials unless it was used for more than 4 hours of sleep. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.